Access Pharmaceuticals this week announced that it has signed a deal under which its CobaCyte and CobOral siRNA delivery technologies will be evaluated by an undisclosed pharmaceutical company.
The delivery approaches are based on Access' so-called Cobalamin technology, which takes advantage of the body's natural vitamin B12-uptake mechanism. A polymer and an siRNA are joined to make a nanoparticle, which is then coated with the vitamin.
According to Access, it will provide oral and intravenous siRNA formulations to the pharmaceutical firm for evaluation.
Successfully developed compounds will be subject to a formal licensing agreement, Access noted.
Additional terms were not disclosed. The deal follows a similar arrangement Access forged earlier in the year (GSN 4/14/2011).